drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous, gene-modified T cells expressing a cooperative/dual chimeric antigen receptor targeting ADGRE2 (EMR2) and CLEC12A (CLL-1) to mediate cytotoxic killing of AML blasts/LSCs while aiming to spare normal myeloid cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a cooperative dual chimeric antigen receptor targeting ADGRE2 (EMR2) and CLEC12A (CLL-1) on AML blasts and leukemic stem cells; antigen binding activates CAR signaling leading to T-cell activation and cytotoxic killing of malignant cells while aiming to spare normal myeloid cells.
drug_name
ADCLEC.syn1 CAR T cells
nct_id_drug_ref
NCT05748197